Description
Title: Beyond CRS and ICANS: CAR T-cell Therapy for CNS Tumors: Nursing Assessment and Management
Presented By:
Christina Baggott PhD, RN, PPCNP-BC, CPON, FAPHON
Ashley Jacobs, RN, BSN, CPN, BMTCN
Courtney Erickson, RN, BSN
Course Overview: Presented at the 2025 Spring Education Exchange (SEE) this course presents Diffuse midline gliomas (DMG) are aggressive central nervous system tumors with limited treatment options and poor survival outcomes. GD2-CART therapy, which uses genetically engineered T-cells to target GD2 markers on DMG cells, represents a promising innovation. Locoregional delivery through ventricular reservoirs, such as Ommaya, improves efficacy while minimizing systemic toxicity.
This course focuses on essential nursing assessments and the management of tumor inflammation-associated neurotoxicity (TIAN), classified as type 1 (mechanical) or type 2 (electrical). Nurses will learn to identify and manage toxicities from mild to life-threatening, perform comprehensive evaluations, and provide psychosocial support.
The course also addresses care strategies for both general and intensive care settings, ensuring nurses are prepared to support GD2-CART patients throughout their treatment journey.
This Session will Explore:
- Overview of GD2-CART therapy and its role in treating diffuse midline gliomas
- Mechanism of action and benefits of locoregional administration via ventricular reservoirs
- Nursing assessments for patients receiving GD2-CART therapy
- Recognition and management of TIAN (type 1 mechanical and type 2 electrical)
- Strategies for managing toxicities from mild to life-threatening
- Comprehensive evaluation techniques for neurological and systemic effects
- Psychosocial support approaches for patients and families during treatment
- Care considerations for both general and intensive care settings
Upon successful completion of this course, nurses will earn 1 NCPD hours associated with this activity.
Association for Pediatric Hematology Oncology Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation. Provider approved by the California Board of Registered Nursing, Provider Number 14513.
Individual Learning Needs Assessment (ILNA) Coding
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. You may claim 1 NCPD in one of the following ILNA categories: 1 ILNA in Disease Related Biology OR Care of the Pediatric Hem/Onc Patient OR Supportive Care, Palliative Care and Symptom Mgt OR
Pediatric Oncologic and Hematologic Emergencies OR Pediatric Hem/Onc Nursing Practice OR
Treatment OR Foundations of Transplant OR Transplant Process and Infusion OR
Cellular Collection, Prep Regimen and Infusion OR Early Post Transplant Management and Education OR Late Post Transplant Management and Education OR Quality of Life OR
Professional Performance
Please reach out to the Education Team at education@aphon.org with your name, the email associated with your APHON account, and the above ILNA category you would like to have reflected on your certificate, and APHON can update your completion certificate to reflect your choice.
Any questions? Contact education@aphon.org
